CONGRESS | #ASCO21 | @NBahlis presents the initial results of elranatamab, a novel BCMA/CD3 bispecific antibody, in triple-class exposed patients. Deep and durable responses were achieved even in BCMA-exposed pts. Of note, pts did not receive premedication for CRS. #mmsm pic.twitter.com/TEvg5h6CmC
— Multiple Myeloma Hub (@MM_Hub) June 8, 2021